Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
  • A company that specializes in R&D and manufacturing of various finished formulations is looking for suppliers of BP Grade Allantoin (5 kg) API for commercial purposes. The suppliers must support this enquiry with DMF (open part) & CoA.
    28 May 2024

    Comment Comment

    Reply text-arrow

    A Company that focuses on manufacturing and development of various finished formulations is looking for suppliers of Oxybutynin Hydrochloride (100 g) API for development purposes. The suppliers must support this enquiry with DMF (open & closed part) & CoA.
    28 May 2024
  • A company that focuses on manufacturing of various finished formulations including tables, syrups & creams is looking for suppliers of Cloxacillin Sodium (100 kg) API for commercial purposes. The suppliers must support this enquiry with DMF (open part) & CoA.
    28 May 2024

    Comment Comment

    Reply text-arrow

    A company that focuses on distribution of various pharmaceutical, nutraceutical & cosmetic products is looking for suppliers of Zolpidem Tartrate (10 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    28 May 2024

    Comment Comment

    Reply text-arrow

  • A contract manufacturing organization (CMO) that focuses on manufacturing of various nutraceutical & pharmaceutical finished formulations is looking for suppliers of Pinaverium Bromide (5 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    28 May 2024

    Comment Comment

    Reply text-arrow

    A company that focuses on the development of innovative medicines is looking for suppliers of Semaglutide (1 kg) API for development purposes. The suppliers must support this enquiry with CoA.
    28 May 2024
  • A CMO which focuses on manufacturing and delivering branded, generic formulations and active pharmaceutical ingredients (API’s) of essential phospholipids to customers is looking for suppliers of Various Finished Formulations for commercial purposes. The required quantity is 2,00,000 Units.
    1. Trimeperidine 2% Injection
    2. Rifampicin (0.15 mg/ml) Injection
    14 May 2024
    A large pharmaceutical company based in India that devotes itself to R&D, production, marketing and sales of active pharmaceutical ingredients and pharmaceutical intermediates is looking for suppliers of Various Finished Formulations for commercial purposes. The required quantity is MOQ. The supplier must support this enquiry with EU GMP & Serialization availability.
    1. Dapagliflozin (5 mg) + Metformin (1000 mg) IR Tablets
    2. Dapagliflozin (5 mg) + Metformin (850 mg) IR Tablets
    06 May 2024
  • A company that focuses on manufacturing and distribution of various finished formulations used in surgery, dermatology, orthopedics, pediatrics, cardiology, gynecology, therapy and other areas of modern medicine is looking for suppliers of Gynanfort suppositories for commercial purposes. The required quantity is 30,000 packs for first year. The supplier must support this enquiry with GMP, ISO & e-CTD dossier.
    26 Apr 2024
    A large pharmaceutical company that devotes itself to R&D, production, marketing and sales of active pharmaceutical ingredients and pharmaceutical intermediates is looking for suppliers of Citicoline (1g/ dose) Sachet- 10 ml pack for commercial purposes. The required quantity is MOQ. The supplier must support this enquiry with EAEU.
    18 Apr 2024
  • A global healthcare leading company that focuses on the research, development and manufacturing of branded generic medicines, medical devices & nutritional products is looking for GMP certified CMO for hormonal gel manufacturing for topical application. The required packaging is customized plastic tube. The project launch time is in 2031. The geographical preference for service provider is Europe.
    23 May 2024
    A company that provides a range of full R&D pharmaceutical services and drug delivery solutions is looking for GMP & EMEA/ USFDA Certified CDMO to manufacture powders & granules. The required packaging is PET-glass bottle/ sachet stick pack. The country of distribution is Europe & United States. The geographical preference for service provider is Canada, EMEA & United States.
    19 Apr 2024
  • A company that focuses on development of innovative prescription products for aesthetic medicine and medical dermatology is looking for CMO to manufacture Liniment for the treatment of Crow’s feet and hyperhidrosis. The required packaging is 1 ml in dropper. The project launch time is in 2026. The required quantity is 10 batches of 100 kg. The country of distribution is United States. The geographical preference for service provider is United States.
    22 Feb 2024
    A company based in United States that focuses providing solutions in areas specifically defense, intelligence, health & bioscience, transport, energy and critical infrastructure is looking for GMP certified CDMO for intravenous injectables. The country of distribution is United States.
    09 Feb 2024
  • A company that focuses on manufacturing and distribution of various finished formulations including tablets, capsules, dry powder sachets and ointments is looking for suppliers of Various Excipients for commercial purposes. The suppliers must support this enquiry with CoA.
    1. BP Grade PVPK-30 (500 kg) Excipient
    2. BP Grade Purified Talcum (500 kg) Excipient
    3. BP Grade Colloidal Silicon Dioxide (200 kg) Excipient
    4. Dicalcium Phosphate (3 MT) Excipient
    28 May 2024

    Comment Comment

    Reply text-arrow

    A company that focuses on manufacturing and export of active pharmaceutical ingredients is looking for suppliers of various excipients for development purposes. The supplier must support this enquiry with CoA.
    1. USP/EP Grade Edetate disodium (0.5 kg - 1 kg) Excipient
    2. USP/EP Grade Sodium Carbonate (0.5 kg - 1 kg) Excipient
    3. USP/EP Grade Sodium Bisulfite (100 g - 500 g) Excipient
    4. USP/EP Grade Sodium Metasulfite (100 g - 500 g) Excipient
    5. USP/EP Grade Butylated Hydroxyanisole (100 g - 500 g) Excipient
    6. USP/EP Grade Butylated Hydroxytoluene (100 g - 500 g) Excipient
    7. USP/EP Grade Sodium Ascorbate (0.5 kg - 1 kg) Excipient
    16 May 2024
  • A company that focuses on manufacturing and distribution of various finished formulations including tablets, capsules, dry powder sachets and ointments is looking for suppliers of Various Excipients for commercial purposes. The suppliers must support this enquiry with DMF & CoA.
    1. USP /BP Grade Butylated Hydroxy Toluene (1 kg) Excipient
    2. Hydroxy Propyl Methyl Cellulose Excipient
    03 May 2024
    A CDMO that focuses on manufacturing, development & distribution of various non-sterile oral dosage forms is looking for suppliers of Ph. Eur. Grade Dichloromethane (6 Tons) Excipient for commercial purposes. The supplier must support this enquiry with CEP & DMF.
    23 Apr 2024

Interviews #SpeakPharma

  • "Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"
    This week, SpeakPharma interviews Martin Meeson, CEO of Axplora, a leading and reliable API manufacturing partner to some of the world’s biggest pharma and biotech companies. Meeson discusses Axplora’s expansion in the antibody-drug-conjugate (ADC) space and how it is well-placed to serve the exciting market for glucagon-like peptide 1 (GLP-1) drugs with its industrial footprint and purification technologies across several sites. 🔑 HIGHLIGHTS// API manufacturing partner to some of the world’s biggest pharma and biotech companies As a leader in the pharmaceutical industry, what inspired you to join Axplora? And, what do you consider the most rewarding aspect of your role as its CEO? When you look at Axplora as the custodian of strong brands like Farmabios, Pharmazell and Novasep you cannot help but be intrigued by what such breadth of offering and depth of technical expertise can achieve. Well, I was certainly intrigued! As a leader in the pharma space, the opportunity to guide an organization with several decades of experience is inspiring for me. For example, our site in Leverkusen was founded over 150 years ago by Alfred Nobel. With every meeting and site visit, I get increasingly impressed by the capabilities of the people that I meet. Now, it is my job to make sure that these capabilities are given the best opportunity to serve. In this sector, we have the privilege of working with our partners to supply and develop medicines that have such a positive impact on people’s lives. This for me is the most rewarding thing that we do. Sometimes the work that we do can seem a little far away from the patient. I always take time to remind myself, my staff, and hopefully also your readers of what we are doing and how our work impacts others. 🔑 HIGHLIGHTS// strong brands like Farmabios, Pharmazell and Novasep / positive impact on people’s lives How have recent industry developments influenced both API manufacturing and CDMO sectors, and what specific strategies has Axplora implemented to adapt to these changing market dynamics while maintaining its commitment to quality and innovation? As a CDMO, when you partner with us, there is always a focus on reliable supply, and we are still haunted by the challenges all of us faced during the pandemic. At Axplora, we have implemented numerous initiatives to increase the robustness of supply, particularly in looking at advances in sourcing and horizontal integration both within and across our network. At the same time, we have a strong focus on the impact that we are having on the planet and Axplora’s work in this area is tremendous — from increasing the amount and efficacy of waste management, notably the current programs around solvent recovery and recycling, to implementing more environment-friendly technologies such as electrochemistry. I am particularly excited by the cutting-edge work on moving to completely new processes that are water-based rather than solvent-based, creating a step change in impact for us and our partners. In addition, as a CDMO you have to constantly look at where your services fit within evolving markets. Axplora’s expansion in the ADC sector is an excellent example of tracking and investing in emerging technologies. Of note also is the current demand for GLP-1 medicines, and Axplora is well-placed to serve this exciting market with our industrial footprint in small molecules and purification technologies across several sites in our network. 🔑 HIGHLIGHTS// increase the robustness of supply / efficient waste management programs and environment-friendly technologies Can you discuss any recent advancement or breakthrough in API manufacturing or CDMO services at Axplora that have contributed to the company’s success? Our investment in ADC expansion is a key strength. Our Novasep business has some of the world’s leading capabilities in API manufacturing and purification. It is known worldwide for these capabilities. With increasing demand for GLP-1 drugs and the amazing impact they are having on patients globally, we are ready to support this growth across our extensive network. The race to oral dose medicines in this space is particularly exciting, and Axplora is looking forward to treating the vast patient population in diabetes and obesity. 🔑 HIGHLIGHTS// expansion in the ADC sector / treat the vast patient population in diabetes and obesity Looking ahead, what are some of the trends or developments you foresee in API manufacturing and CDMO services, and how is Axplora preparing to stay ahead of the curve in this ever-evolving pharmaceutical landscape? Whilst the landscape is evolving rapidly, regulations are not necessarily able to keep pace with the development of new molecules. The pandemic revealed that things can move more quickly. When I look at the challenging new regulation in adjacent spaces like cell therapy, I wonder how that pace can be applied to our sectors. To that end, you have to remain agile and responsive to customer needs. We have to ensure we invest to grow our capacity in the right areas. Our recent investments in Farmabios in Gropello Cairoli (Italy) to support our thriving steroids business and in Pharmazell in Vizag (India) to advance our specialty business are clear indications of how we can do this very successfully. It would be easier if I could point to just one thing that we are doing, but that is not how we win. The only way to stay ahead is by making a myriad of large and small adjustments and evolutions and that is where the Axplora group excels. Finally, one element I should mention is that we are part of a global supply chain. Therefore, our broad network stands ready to supply medicines to multiple geographies. Our investments reflect our worldwide customer base and ambitions. We are here to serve our partners and their patients. 🔑 HIGHLIGHTS// recent investments in Farmabios in Italy and Pharmazell in India / ready to supply medicines to multiple geographies

    Impressions: 613

    https://www.pharmacompass.com/speak-pharma/axplora-s-leading-position-in-adcs-and-how-it-is-well-placed-to-serve-the-burgeoning-glp1-market

    23 May 2024

Data Compilation & Company Tracker #PharmaFlow

  • DMF submissions from China jump 42% as India continues to top list in Q1 2024
    Generic drugs play a crucial role in providing access to life-saving drugs at affordable prices. To that end, drugmakers submit Drug Master Files (DMFs) or their ‘recipes for making generics’ to the US Food and Drug Administration (FDA) for review. Of these, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs.PharmaCompass has been reviewing Type II submissions for several years now. We have noticed that these filings have been increasing in recent years. There has been a 33.5 percent increase in Type II DMF submissions since Q1 2018 (when 176 Type II DMFs had been submitted). However, at 235, the first quarter (Q1) of 2024 saw only a 1.3 percent increase in DMF submissions over Q1 2023. In Q1 2023, DMF submissions had increased by 21.5 percent (over Q1 2022).Of the 235 Type II submissions received by the FDA in Q1 of this year, only 35 (or around 15 percent) had their review completed under the Generic Drug User Fee Act (GDUFA). The total number of reviews completed by the US federal agency so far this year is 129.In all, FDA received 353 Type II, III, IV, and V DMF submissions, compared to 291 in Q1 2023, an increase of 21.3 percent.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available)DMF submissions from India dip 1.8%; China witnesses 42% rise in filings As has been the trend, India (dubbed as the pharmacy of the world) and China filed the maximum DMF submissions, with 107 and 101 submissions respectively. However, DMFs filed by Indian companies saw a marginal dip of 1.8 percent in Q1 2024 — in Q1 2023, Indian companies had filed 109 Type II DMFs. Meanwhile, DMF filings by Chinese drugmakers increased 42.2 percent in Q1 2024, up from 71 in Q1 2023.India’s MSN Laboratories was the clear leader with 15 DMF submissions to the FDA, while China’s Sichuan Elixir Pharmaceutical came a distant second with nine submissions. Indian drugmakers Aurobindo Pharma and Global Calcium (with seven submissions each) were tied at third position. There were two players at the fifth spot — India’s Dr. Reddy’s Laboratories and China’s Zhejiang Jingsheng Pharmaceutical — as both these drugmakers registered six submissions each.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Diabetes, cancer drugs emerge as hot molecules in Q1 2024Approved in June 2020, triheptanoin is the first and only FDA-approved treatment for children and adults with long-chain fatty acid oxidation disorders (LC-FAOD). At five, triheptanoin saw the maximum DMF filings. Four of those applications have already been positively reviewed.Anti-diabetic drug sitagliptin phosphate monohydrate saw four DMF filings. Empagliflozin, the API found in Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, drew three DMF filings in Q1 2024.In the US, Jazz Pharmaceuticals’ Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC). Three DMF applications were submitted for lurbinectedin. Similarly, ruxolitinib phosphate, used for the treatment of patients with intermediate or high-risk myelofibrosis, also received three DMF applications.Semaglutide — the glucagon-like peptide-1 receptor agonist that catapulted Novo Nordisk to the position of the most valuable public company in Europe — received three DMF filings. Semaglutide’s arch rival, tirzepatide, also drew three DMF filings.AstraZeneca’s Brilinta (ticagrelor) plus aspirin is currently approved in over 115 countries for the prevention of stroke, heart attack, and other events in adults with acute coronary syndrome (ACS). Ticagrelor received three DMF submissions. Vonoprazan fumarate, a first-in-class potassium-competitive acid blocker to treat acid-related diseases, also received three DMF submissions.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Eighteen DMFs filed for first time in Q1 2024 During the first quarter of this year, 14 drugs saw first time filing of DMFs. Together, these 14 drugs attracted 18 DMF filings with tirzepatide topping the list with three submissions from Chinese companies.The 14 drugs that saw first time filing were clascoterone, capmatinib hydrochloride, niraparib tosylate monohydrate, vibegron, cabozantinib sulfate, ruxolitinib hemifumarate, ripretinib, ruxolitinib, ruxolitinib mesylate, tucatinib hemiethanolate, tecovirimat, tirzepatide, tolvaptan povidone, and azilsartan.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Our viewUntil 2020, DMF submissions by Indian companies used to be double those of Chinese and American firms put together. In 2022, DMF filings from India began to dip, while submissions by Chinese companies began to rise. In the first half of 2023, there was a 46.5 percent rise in DMF submissions from China. The gap between DMF filings by India and China has narrowed down considerably this year. The reasons behind this phenomenon may be multiple. But it definitely implies that America will find it increasingly difficult to reduce its reliance on China.

    Impressions: 729

    https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-from-china-jump-42-as-india-continues-to-top-list-in-q1-2024

    #PharmaFlow by PharmaCompass
    23 May 2024

Monthly Stock Recap #PipelineProspector

  • Pipeline Prospector April 2024: Indices dip amid muted Q1 results; Vertex acquires Alpine Immune for US$ 4.9 bn
    Pharma indices had begun to recede in March. Their red streak accelerated in April with the Nasdaq Biotechnology Index (NBI) falling 6 percent from 4429.97 in March to 4162.33 last month and the SPDR S&P Biotech ETF (XBI) index tripping 10 percent from 94.34 to 84.62. Similarly, the S&P Biotechnology Select Industry Index (SPSIBI) was down 11 percent from 7402.50 to 6584.40 in April.This muted performance was also reflected in the first quarter (Q1) results. Biogen, Biomarin, Roche, Gilead, Merck, Sanofi, BMS and Johnson & Johnson announced their Q1 results in April. While Roche and Biogen reported a drop in revenues, BMS posted a loss in Q1, even though its revenues increased. And Sanofi reported a 14.7 percent drop in operating income due to competition from generics and currency fluctuations. BioMarin, Gilead and Merck reported a 9 percent, 5 percent and 9 percent increase, respectively, in their Q1 revenues over Q1 2023.There were a handful of deals announced last month, the biggest being Vertex Pharmaceuticals’ acquisition of Alpine Immune Sciences for US$ 4.9 billion. The deal gives Vertex access to Alpine’s protein-based immunotherapies for autoimmune diseases.Japanese drugmaker Ono Pharmaceutical agreed to acquire Massachusetts-based Deciphera Pharmaceuticals for US$ 2.4 billion. The acquisition gives Ono access to Deciphera`s oncology pipeline. Denmark’s Genmab agreed to acquire privately-owned ProfoundBio for US$ 1.8 billion. ProfoundBio has three next-generation antibody drug conjugate (ADC) candidates in its pipeline that will now go to Genmab.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel)FDA okays ImmunityBio’s Anktiva, Day One’s Ojemda for bladder, brain cancerLike March, April too saw several significant drug approvals, especially in oncology. ImmunityBio (its stock was up 50 percent in April) won its first US Food and Drug Administration (FDA) approval as the agency greenlit Anktiva as part of a combination therapy to treat a type of bladder cancer. With this approval, Anktiva will compete with Merck’s Keytruda.AstraZeneca (stock up 12 percent) and Daiichi Sankyo’s Enhertu has been granted accelerated approval in the US to treat adult patients with HER2-positive solid tumors that have spread or cannot be surgically removed. These patients have undergone prior treatment and have no satisfactory alternatives available to them. J&J and Legend’s Carvykti has become the first and only BCMA-targeted therapy approved by the FDA for patients with relapsed or refractory multiple myeloma, who have received just one prior line of treatment. The approval is an important milestone in J&J’s plans to make Carvykti a US$ 5 billion-plus asset at peak yearly sales.Day One Biopharmaceuticals’ Ojemda has been granted FDA’s accelerated approval to treat certain types of pediatric brain cancer. The pan-RAF kinase inhibitor has been okayed for patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This is the first FDA approval of a systemic therapy for treating what is the most common form of childhood brain tumor.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel) Basilea’s antibiotic bags FDA nod; Vanda’s Fanapt approved for bipolar disorderThe agency also approved Vanda Pharmaceuticals’ (stock up 25 percent) Fanapt tablets for treating manic or mixed episodes associated with bipolar-1 disorder in adults. The atypical antipsychotic agent has been used for the treatment of patients with schizophrenia since its FDA approval in 2009. This second approval for bipolar-1 disorder patients (who experience manic episodes that last at least seven days) could help revive Fanapt prescriptions.FDA has also approved Basilea Pharmaceutica’s Zevtera, an antibiotic for bacterial infections including multidrug-resistant strains. The US agency has okayed it for three conditions – treatment of adults with Staphylococcus aureus bacteremia, including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections; and adult and pediatric patients with community-acquired bacterial pneumonia.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel) BMS’ schizo drug shows benefit sans weight gain; Imfinzi scores in lung cancer trialA common side effect associated with anti-psychotics is weight gain. However, interim results from a late-stage trial have shown that BMS’ schizophrenia drug KarXT continued to improve symptoms of the severe mental disease even at 52 weeks, and without weight gain.In another phase 3 trial, Imfinzi significantly improved overall survival and progression-free survival in patients with limited-stage small cell lung cancer. This makes this blockbuster drug the first and only immunotherapy to demonstrate survival benefit for this aggressive form of lung cancer. Imfinzi had posted sales of US$ 4.24 billion in 2023.Intra-Cellular Therapies said a phase 3 study of its drug Caplyta in people with major depressive disorder (MDD) met both its primary and key secondary endpoints. Given once daily as an adjunctive therapy to antidepressants, Caplyta 42 mg significantly beat the placebo at improving depression severity.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel) Zepbound shows benefit in sleep disorder; Novartis’ Fabhalta reduces proteinuriaEli Lilly’s popular weight-loss drug Zepbound cut irregular breathing episodes associated with a common sleep-related disorder – obstructive sleep apnea (OSA). Treatment with Zepbound reduced the frequency of irregular breathing episodes by as much as 63 percent in adults with OSA and obesity across two late-stage trials. Lilly plans to submit the findings to FDA to expand Zepbound’s use for OSA. Roche’s Genentech said its drug Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A late-stage study pitted the Columvi-chemotherapy combination against a rituximab-chemotherapy combination in patients who received at least one prior line of therapy and are not candidates for autologous stem cell transplant. Patients in the Columvi group lived longer.In another late-stage trial, Novartis` drug Fabhalta reduced proteinuria (protein in the urine) in patients with IgA nephropathy by 38.3 percent. The Swiss drugmaker filed for FDA’s accelerated approval using the data, and the agency has granted it priority review.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel) Our viewAt the start of 2024, the US market saw inflation falling and there were talks of interest rate cuts by the Federal Reserve. But few months on, the outlook has darkened a bit with inflation refusing to let off steam and economic output slowing down in the US. This is getting reflected in the pharma indices and the Q1 results of several drugmakers. Though overall, we have faith in the pharma sector’s spirit of innovation and its zest for dealmaking. Despite the macroeconomic challenges, there is hope that the other three quarters of 2024 will look better.Access the Pipeline Prospector Dashboard for April 2024 Newsmakers (Free Excel) 

    Impressions: 759

    https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-april-2024-indices-dip-amid-muted-q1-results-vertex-acquires-alpine-immune-for-us-4-9-bn

    #PipelineProspector by PharmaCompass
    09 May 2024

Weekly News Recap #Phispers

  • Astra targets US$ 80 bn revenue by 2030, invests US$ 1.5 bn in ADC plant; Lilly’s weekly insulin scores late-stage wins
    In this week’s news, AstraZeneca has laid out an ambitious plan to achieve US$ 80 billion in revenue by 2030. The drugmaker also announced an investment of US$ 1.5 billion to set up an antibody drug conjugates (ADCs) plant in Singapore.In news from clinical trials, Eli Lilly’s once-a-week insulin shot — efsitora — scored two late-stage wins. GSK’s long-acting experimental asthma drug depemokimab reduced asthma attacks in two late-stage trials. And Bayer’s non-hormonal menopause drug significantly reduced hot flashes in two phase 3 studies.In approvals, the US Food and Drug Administration (FDA) has granted accelerated approval to Amgen’s targeted immunotherapy Imdelltra for adults in the advanced stages of small cell lung cancer that has proved hard to treat or has worsened despite chemotherapy. FDA also okayed the first two biosimilars for Regeneron’s blockbuster eye drug Eylea.A group of cancer victims have sued Johnson & Johnson accusing it of fraud in its plans to settle the talc lawsuits.In deals, Biogen is acquiring Human Immunology Biosciences (HI-Bio) for up to US$ 1.8 billion, Johnson & Johnson is buying California-based Proteologix for US$ 850 million and Eli Lilly has inked a potential US$ 1.1 billion collaboration with Aktis Oncology.Astra sets 2030 revenue target at US$ 80 bn, invests US$ 1.5 bn to build ADC facilityAstraZeneca has laid out an ambitious plan to deliver US$ 80 billion in total revenue by 2030. That will be a 75 percent leap from the US$ 45.8 billion in revenue it posted in 2023. Astra expects to launch 20 new medicines by 2030. Astra’s targets are driven by its cancer portfolio, as also its biopharmaceuticals and rare disease portfolios. The drugmaker’s oncology portfolio had brought in US$ 17.1 billion last year.The update comes on the heels of Astra’s investment of US$ 1.5 billion in building a manufacturing facility in Singapore for ADCs to enhance the global supply of its ADC portfolio.Meanwhile, Pfizer has launched a new multi-year program to cut costs by around US$ 1.5 billion by 2027-end. Last year, it had announced a US$ 4 billion cost cutting plan.Lilly’s weekly insulin proves to be as effective as daily doses in two late-stage trialsEli Lilly’s once-weekly insulin jab, efsitora, showed blood sugar reduction consistent with the daily insulins widely used today by patients with type 2 diabetes. Efsitora met its primary endpoints in two phase 3 trials. Lilly is in a race with Novo Nordisk to bring to market weekly injections with long-acting insulins, which would lower the treatment burden for diabetes patients.There was disappointing news from its rival Novo on its long-acting weekly insulin — Awiqli (insulin icodec). FDA said the use of this med came with an increased risk of low blood sugar in patients with type 1 diabetes, who are more insulin-dependent. An FDA panel will meet on May 24 to review Novo’s application seeking approval for this once-weekly insulin.GSK sells remaining stake in Haleon; scores trial wins for asthma drug: GSK has raised £ 1.25 billion (US$ 1.52 billion) by dropping the remainder of its stake (4.2 percent) in Haleon. It also touted two late-stage wins for its experimental asthma drug depemokimab. The med reduced asthma attacks over a year at a rate that was clinically significant.Bayer’s menopause drug reduces hot flashes in trials: Bayer said its non-hormonal drug, elinzanetant, significantly reduced debilitating bursts of body heat (hot flashes) associated with menopause. This tees it up to become only the second non-hormonal drug to do so after Astellas’ Veozah (fezolinetant).Amgen’s med grabs FDA’s accelerated nod for small cell lung cancerFDA has granted accelerated approval to Amgen’s Imdelltra (tarlatamab-dlle) for adults in the advanced stages of small cell lung cancer (SCLC) that has proven to be hard to treat or has worsened despite platinum-based chemotherapy. The bi-specific antibody is a targeted immunotherapy that shrank tumors in 40 percent of patients in a mid-stage trial. SCLC is usually more aggressive and deadlier than non-small cell lung cancer.First biosimilars for Regeneron’s Eylea okayed: FDA has approved the first interchangeable biosimilars to Eylea (aflibercept) to treat macular degeneration and other eye conditions. The US agency greenlit Biocon Biologics’ Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen’s Opuviz (aflibercept-yszy) to be used as a substitute for Regeneron’s blockbuster eye drug.Cancer victims sue J&J over fraudulent bankruptciesA group of cancer victims have sued Johnson & Johnson accusing it of fraud for the repeated efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.Biogen to buy HI-Bio for up to US$ 1.8 bn; Merck KGaA to buy Mirus BioBiogen has agreed to acquire Human Immunology Biosciences (HI-Bio) for up to US$ 1.8 billion, including an upfront payment of US$ 1.15 billion. The deal gives Biogen a promising candidate — felzartamab — that may be a cure for a range of immune-mediated diseases.Meanwhile, Merck KGaA has agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for cell and gene therapies.J&J to buy Proteologix for US$ 850 mn: Johnson & Johnson is acquiring Proteologix for US$ 850 million in cash to advance its dermatology portfolio with the opportunity to address significant unmet need in atopic dermatitis.Aktis in radiopharma deal with Lilly: Aktis Oncology is collaborating with Eli Lilly to discover and develop novel anti-cancer radiopharmaceuticals. Aktis will receive an upfront payment of US$ 60 million, and will be eligible for milestone payments of US$ 1.1 billion. 

    Impressions: 357

    https://www.pharmacompass.com/radio-compass-phisper/astra-targets-us-80-bn-revenue-by-2030-invests-us-1-5-bn-in-adc-plant-lilly-s-weekly-insulin-scores-late-stage-wins

    #Phispers by PharmaCompass
    23 May 2024

Content #LearnMore

  • View Sharp
    View Sharp's clinical trial supply & contract pharmaceutical packaging services for injectables and oral dosage forms on PharmaCompass. What is pharmaceutical contract packaging and how is Sharp a reliable packaging partner for the pharmaceutical and biotech industries? Pharmaceutical packaging can be defined as a set of operations including filling, sealing, packaging, and labeling of semi-finished or finished products. Pharma packaging is an economical means to present, preserve, identify, provide information, maintain product integrity, and ensure stability. It also plays a crucial role in the transportation of sensitive and strictly controlled products. Pharmaceutical contract packaging refers to packaging that is executed and supplied by a licensed third-party service provider that comprises both initial packaging and repackaging. These contract packaging service providers may offer clinical and commercial packaging solutions for pharmaceutical products. Pharmaceutical contract packaging organizations are well-equipped to offer a comprehensive range of primary, secondary, and tertiary packaging solutions. Primary packaging surrounds the pharmaceutical formulation and includes bottles, blisterings, pouches, sachets, tubes, auto-injector pens, etc. Whereas secondary packaging offers further external protection and includes artwork design, labeling for parenteral and injectables, child-resistant and compliance prompting packaging, etc. Additionally, tertiary packaging is used during transportation to absorb physical impacts, moisture, and dust and includes cardboard boxes, stretch wraps, shrink films, and wooden and plastic pallets. Sharp is a leading contract packaging organizations that offer pharmaceutical packaging services among others. It has more than 70 years of experience in pharmaceutical clinical packaging, clinical trial supply services, and small-scale sterile manufacturing. Sharp has more than 2,000 employees who work in its state-of-the-art GMP facilities in the US, UK, Belgium, and the Netherlands. Sharp, offers contract manufacturing and packaging services and support from phase I clinical trial supplies to commercial launch and lifecycle management to its pharmaceutical and biotechnology partners across the world. It has deep expertise in clinical trial packaging and labeling along with a skilled global design team that utilizes cutting-edge software and technology ensuring patient-friendly and differentiated packaging for drug products. Apart from this, Sharp is also a reliable partner for sourcing packaging material and offers integrated pharmaceutical packaging and labeling services along with over-encapsulation of oral solids and the production of placebo capsules for study blinding. Sharp is a contract packaging organization that offers commercial packaging services including contract blister packaging services, bottle packaging, sachet packaging, injectable packaging, and other solid dose packaging solutions. Additionally, it offers clinical packaging and labeling solutions such as clinical trial material packaging, clinical trial packaging and labeling, clinical trial logistics and packaging, and clinical trial supply services, or clinical supplies. Its clinical and commercial packaging services are outlined below: Clinical Packaging Solutions Sharps clinical packaging solutions encompass primary packaging and labeling and secondary packaging. Its pharmaceutical primary packaging offers reliable clinical packaging services, clinical supply chain services, primary packaging solutions, and cold-chain secondary packaging and labeling at 2-8°C, -20°C, and even at -70°C. Sharp also provides reliable clinical pharma packaging services and labeling, secondary packaging solutions, pharmaceutical clinical packaging and labeling solutions along with expertise and capabilities in handling cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C. Commercial Packaging Solutions For more than 65 years, Sharp has been providing a full range of commercial primary and secondary packaging solutions, blister packaging, and contract manufacturing and packaging services for pharmaceutical oral solid dosage forms. It offers contract blister packaging services and bottle packaging for pharmaceutical drug products. Apart from this Sharp provides pharma packaging contract services for small and large-volume batch sizes of injectables. It offers pharmaceutical packaging services for cold chain storage, packaging in temperature- and light-controlled environments, serialization, and customized distribution. Additionally, Sharp is involved in the pharma packaging of oral solids, liquids, and semi-solids. Moreover, Sharp is a premier commercial packaging service provider for high-value, low-volume gene therapy. It also offers pharmaceutical packaging services, expertise, and powerful technology that facilitates product serialization and aggregation. Therefore, Sharp’s pharma packaging contract services, spanning from clinical supplies to commercial include pharma clinical trial material manufacturing, clinical primary packaging services, clinical secondary packaging solutions, clinical trial packaging and labeling, and clinical trial logistics and packaging. Furthermore, Sharp’s contract manufacturing and packaging services encompass commercial pharma packaging solutions and labeling and supply services. Consequently, all the aforementioned offerings position Sharp as a one-stop-shop contract pharmaceutical packaging service provider for clinical and commercial scales. How does Sharp address challenges related to clinical labeling and secondary packaging? Sharp has over 70 years of experience and is a pioneer in clinical trial supply services and pharmaceutical packaging. Dedicated to the right-first-time principle, Sharp is a reliable partner for secondary packaging and clinical pharmaceutical labeling and packaging. It offers a wide range of quick, scalable clinical trial packaging services and labeling and packaging solutions in all formats, with capabilities spanning the complete lifespan of investigational medicinal products (IMPs). Moreover, Sharp can also address challenges related to packaging and labeling and offers pharmaceutical packaging and labeling services and clinical packaging and labeling services to its clients. Additionally, its clinical packaging and labeling solutions also include in-house auxiliary variable data printing outsourced booklet labels, client-supplied randomization fully supported, and annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design. Sharp's pharmaceutical packaging and labeling services include single and multi-panel labels and booklets, 2D barcoding capabilities, randomized and open, 128 barcoding. It also offers regulatory and translation services, sequentially numbered, variable text, code break, and randomized generation among other clinical packaging and labeling solutions. Sharp is a leader in providing pharmaceutical clinical packaging, contract packaging services, and labeling and supply services in compliance with strict regulatory guidelines. It has special pharma packaging and labeling expertise and capabilities for packaging drug products. Sharp addresses various challenges related to pharma packaging and labeling which includes: Sharp can provide cold-chain pharmaceutical labeling and packaging from 2-8°C to -70°C for drug products that need low temperatures for their transportation and storage. Sharp can support the secondary packaging for most complex drug candidates, such as controlled substance packaging (DEA schedule I-V), and has the capabilities to scale up to commercial supplies. Its design and logistics staff can also assist with the challenges of blinding products and syringes for clinical trial services. Sharp does this by providing annex 13 compliant and 21 CFR Part 11 compliant PRISYM software for label design, client-supplied randomization fully supported, and in-house auxiliary variable data printing outsourced booklet labels. With issues related to timely delivery and efficient labeling, Sharp provides pharmaceutical labeling and packaging solutions by using Scan assembly technology and Interactive Response Technologies (IRT), storage, and distribution. To overcome the label readability issues for clients worldwide, Sharp designs and prints multilingual clinical labels. Therefore, Sharp acts as a one-stop-shop packaging organization that provides pharmaceutical contract packaging services, clinical primary packaging services, primary and secondary clinical packaging, and labeling and supply services to its clients worldwide. What range of packaging design and kitting services does Sharp offer? Sharp is a market leader in the design and delivery of primary and secondary packaging. Due to its structural, graphic, and design engineers as well as its understanding of supply chain and regulatory issues, Sharp excels in pharmaceutical packaging. Sharp has years of experience in creating cutting-edge pharma packaging solutions. It is skilled in brand creation, modifying current artwork, marketing research, FDA filing standards, 3D rendering, senior, child-friendly, or child-resistant design, and labeling and supply services. Sharp's global design team provides the creativity and accuracy required to design highly functional and compliant primary and secondary commercial and clinical pharma packaging services. Sharp offers a wide range of design services and pharmaceutical packaging solutions using the latest tools and technologies to guarantee premium and user-friendly product packaging. Additionally, it provides structural and graphic design development for quick launch and regular upgrades for commercial artwork. Sharp’s wide range of packaging design services for pharmaceutical products includes: Artwork Design Services: Sharp can provide pharma packaging contract services including customized artwork as per specific markets from initial mock-ups to product registration. Packaging Samples: Sharp’s contract pharmaceutical packaging services can create production-quality models for use in marketing presentations, human factor research, and photography that closely match the commercial package. Tray Design: Sharp precisely assesses product components to create a tray design that best suits the drug. 3D Printing: Sharp can rapidly confirm that all product components fit by using its technology to create 3D printed prototypes of trays and other packaging component designs. Shipper and Pallet Design: The structural designers at Sharp develop pallet layouts and shippers based on finished items to guarantee drug safety during distribution and storage. CR/SF Compliant Design and Testing: Sharp offers pharmaceutical contract packaging services and can determine the level of toxicity in child-friendly packaging. Various structural design services offered by Sharp include end-user interactions and compliance, child-resistant, senior-friendly (CR/SF) design, tamper evident features, multiple-component kitting requirements, and sustainable or specified materials. Additionally, Sharp’s graphic design capabilities include serialization artwork, brand identity, complete package graphics, product and package illustrations, and late-stage customization. Sharp’s broad range of tailored kitting options for medical devices, pharmaceuticals, and biotechnology calls for the packaging of multiple components into a single, self-contained unit. The design team at Sharp offers commercial packaging solutions and helps clients create a kit that best meets the end-user needs and product specifications. Its kitting services include labeling, tray packing, and boxing with comprehensive verification inspection to ensure the highest level of quality. How does Sharp manage the packaging of sterile formulations to ensure product integrity? Sharp has almost seven decades of packaging experience and it provides pharmaceutical packaging solutions for sterile and non-sterile formulations while maintaining the integrity and quality of products. It offers contract pharmaceutical packaging services and package design services from its US and EU facilities for injectables containing both small and large-volume batch sizes. For product launch and sample programs, its international design team works with clients to provide pharma packaging solutions and determine the optimal vial, prefilled syringe, and autoinjector packaging options. Through its partnership with Berkshire Sterile Manufacturing (BSM), Sharp also offers small-scale isolator-based sterile fill-finish options. It specializes in pharmaceutical clinical packaging and commercial packaging in cold chain storage, packaging in temperature and light-controlled environments, and specialty distribution for injectable drug products.  It also supports multi-country launches from the US and EU. Sharp has experience in parenteral and injectable format labeling and packaging such as vials, autoinjectors, syringes, and pens. Its specialized commercial and clinical services for injectables and parenterals include primary and secondary labeling of vials, IV bags, pre-filled syringes, and IV bottles in ambient, cold and ultra-cold environments, custom label generation, kitting, serialization and aggregation, and storage and distribution. Some of Sharp’s sterile packaging capabilities for injectable drug products include: Vial Labeling and Packaging: Sharp has decades of packaging experience and offers pharmaceutical packaging and labeling services for vials. Its contract packaging services include an automated visual inspection of labeling, tray and carton packing, cartoning of single and multipacks, tamper-evident solutions, cold-chain storage (2-8°C), and ultra-low temperature freezer banks (-20°C/-70°C). In addition to these services, Sharp provides package design, kitting, and segregated suites to handle highly potent APIs (HPAPI), cytotoxins, hormones, serialization and aggregation, and specialty distribution. Autoinjector and Pen Assembly, Labeling, and Packaging: Sharp excels in managing the complexities related to autoinjector or pen device labeling and packaging from its US and EU facilities. Moreover, its YpsoMate autoinjector device delivers a high level of technical accuracy required for the assembly of prefilled syringes into YpsoMate autoinjectors. Sharp’s experts also offer clinical trial packaging services and specialize in managing the challenges related to clinical trial logistics and packaging of biological formulations. Pre-Filled Syringe Assembly, Labeling, and Packaging: Sharp is a leader in the assembly, labeling, and packaging of pre-filled syringes and safety devices. It provides customized commercial and clinical pharma packaging services for both small and large-volume batch sizes for injectables. Small Scale Sterile Fill-Finish: Sharp partners with Berkshire Sterile Manufacturing (BSM) and offers high-quality, manufacturing, packaging, and distribution solutions for flexible fillers, BSM fills vials, cartridges, syringes, and lyophilization. Gene Therapy Clinical and Commercial Packaging: Sharp has over 70 years of experience in packaging complex pharmaceuticals such as low-volume, high-value gene therapies. Sharp is also engineered to provide demand-led supply commercial and clinical services including batch sizes as small as 1 vial, or packaging, labeling, and distribution in cold, ultra-cold, or cryogenic conditions. Sharp also has dedicated facilities in Bethlehem, PA, US, Heerenveen, and the Netherlands for handling gene therapies. These facilities are equipped with HEPA air handling systems, controlled temperature, humidity and dew point, full-sized -80°C freezer banks in dedicated production suites, constant monitoring of time-out-of-refrigeration, and specific freeze-thaw cycles. These facilities help in providing clinical trial packaging services and clinical secondary packaging solutions along with commercial packaging of sterile formulations. What range of pharmaceutical packaging solutions does Sharp offer for solid and liquid drug products? With a history spanning more than 70 years, Sharp is a pioneer in providing pharmaceutical packaging services that include primary and secondary packaging of solid, liquid, and semi-solid drug products for clinical and commercial scales from its state-of-the-art facilities. Sharp offers innovative and economical clinical packaging services for investigational medicinal products (IMP). It also supports the packaging of various dosage forms including bottling of solid formulations, and thermo and cold forming blister packaging for oral solids. Sharp also supports the packaging of powder and OSDs in sachets and pouches, oral and transdermal films in strips, and injectables in vials, syringes, and cartridges. Moreover, it is also involved in the packaging of semi-solids such as cream and ointment in tubes. Some of Sharp’s pharmaceutical packaging solutions for solid and liquid drug products are mentioned below: Bottle Packaging for Solids and Semi-solids: Sharp provides pharma packaging contract services for bottle packaging that include component sourcing, carton printing and in-line cartoning or bundling, comprehensive onsite engineering and validation support, serialization and aggregation, and strict quality control for packaged drugs. Sharp also offers high-quality nitrogen flush bottles and bottle packaging for moisture and oxygen-sensitive drugs. Blister Packaging for Oral Solids: Sharp provides various blister packaging solutions including thermoform and cold form blisters, patient packs, hospital unit dose packs, wallet cards, child-resistant lidding, sustainable foil and blister materials, and multiple products per blister. Apart from this, Sharp’s contract blister packaging services also involve multi-color foil printing, in-house tooling design and fabrication, polymer laminates (Aclar, PVC/PVDC, etc.) heat-seal coating resins, and automated visual inspection. Pouches and Sachets for Solids and Transdermal Patches (Primary and Secondary Packaging Services): Sharp has expertise in pouch and sachet packaging filled with solid dose, powder, thin film, and transdermal patch drug products. Sharp’s solid dose packaging solutions offer considerable pouch and sachet packaging backed by quality operations and project management knowledge. Sharp is home to a sizable assemblage of form, fill, and seal technologies. Based on decades of practical expertise, Sharp uses a wide range of innovative film structure materials, such as coated papers, high-barrier foils, and polymer laminates, and offers pharma packaging contract services. It also can support the production of multiple dosage forms for pharmaceutical products. Oral Thin Film and Transdermal Patches: Sharp provides primary and secondary packaging services for oral thin films and transdermal patches. Sharp specializes in die-cutting and pouching sublingual and oral dissolvable films, and transdermal drug delivery systems, and offers specialized pharmaceutical packaging services through quality procedures. It utilizes the most up-to-date solid dose packaging solutions and processes to safely package and safeguard specialty drug products. Sharp’s oral thin film and transdermal patch capabilities include highly accurate dosing by die-cutting laminated products to any size and shape, in-line printing of drug info, bar codes, lot number, expiration date, serialization with optical character verification (OCV), etc. Therefore, Sharp is a pharmaceutical contract packaging organization that offers clinical services, cold chain packaging, clinical packaging and labeling, and commercial packaging. Its pharmaceutical contract packaging service also encompasses primary and secondary clinical and commercial packaging. 

    Impressions: 400

    https://www.pharmacompass.com/pharma-blog/contract-packaging-primary-and-secondary-packaging-services-offered-by-sharp

    #LearnMore by PharmaCompass
    04 Mar 2024